Arnall J[au] - Search Results

Year	Number of Results
1986	1
1987	1
2014	1
2015	1
2016	2
2017	3
2018	5
2019	14
2020	11
2021	11
2022	15
2023	2

1

Providing medication alternatives during intranasal desmopressin recall.

Koon A, Perciavalle K, Oleis J, Arnall J. Koon A, et al. Among authors: arnall j. J Oncol Pharm Pract. 2022 Jan;28(1):190-193. doi: 10.1177/10781552211037860. Epub 2021 Oct 4. J Oncol Pharm Pract. 2022. PMID: 34605322 No abstract available.

2

Sutimlimab: A Complement C1s Inhibitor for the Management of Cold Agglutinin Disease-Associated Hemolysis.

Moore DC, Arnall JR. Moore DC, et al. Among authors: arnall jr. Ann Pharmacother. 2022 Dec 8:10600280221138802. doi: 10.1177/10600280221138802. Online ahead of print. Ann Pharmacother. 2022. PMID: 36476151 Review.

3

Daratumumab for the Treatment of Multiple Myeloma: A Review of Clinical Applicability and Operational Considerations.

Arnall JR, Maples KT, Harvey RD, Moore DC. Arnall JR, et al. Ann Pharmacother. 2022 Aug;56(8):927-940. doi: 10.1177/10600280211058754. Epub 2021 Dec 28. Ann Pharmacother. 2022. PMID: 34963325 Review.

4

Avatrombopag for the Treatment of Immune Thrombocytopenia and Periprocedural Thrombocytopenia Associated With Chronic Liver Disease.

Tran TB, Downing L, Elmes JB, Arnall JR, Moore DC. Tran TB, et al. Among authors: arnall jr. J Pharm Pract. 2022 Sep 15:8971900221125827. doi: 10.1177/08971900221125827. Online ahead of print. J Pharm Pract. 2022. PMID: 36113085 Review.

5

Pharmacogenomics-guided supportive oncology: A tale of two trials.

Patel JN, Arnall J, Jandrisevits E, Morse AL, Steuerwald N, Copelan E, Walsh D. Patel JN, et al. Among authors: arnall j. Contemp Clin Trials. 2021 Jun;105:106391. doi: 10.1016/j.cct.2021.106391. Epub 2021 Apr 2. Contemp Clin Trials. 2021. PMID: 33819640

6

A Review of Growth Factor Support in Bloodless Autologous Hematopoietic Stem Cell Transplant.

Zhao JC, Arnall JR, Martin AL, Atrash S, Bhutani M, Voorhees P, Avalos B, Copelan E, Ghosh N, Hamadani M, Usmani S, Ford P. Zhao JC, et al. Among authors: arnall jr. Biol Blood Marrow Transplant. 2019 Oct;25(10):e305-e309. doi: 10.1016/j.bbmt.2019.07.003. Epub 2019 Jul 8. Biol Blood Marrow Transplant. 2019. PMID: 31295572 Free article. Review.

7

Real-world experience and considerations on concomitant caplacizumab and anticoagulation in thrombotic thrombocytopenic purpura.

Meek B, Desai N, Moore DC, Tran T, Knovich MA, Arnall J. Meek B, et al. Among authors: arnall j. Ann Hematol. 2022 Nov 28. doi: 10.1007/s00277-022-05049-6. Online ahead of print. Ann Hematol. 2022. PMID: 36441262 No abstract available.

8

Caplacizumab: an anti-von Willebrand factor antibody for the treatment of thrombotic thrombocytopenic purpura.

Hollifield AL, Arnall JR, Moore DC. Hollifield AL, et al. Among authors: arnall jr. Am J Health Syst Pharm. 2020 Jul 23;77(15):1201-1207. doi: 10.1093/ajhp/zxaa151. Am J Health Syst Pharm. 2020. PMID: 32588878 Review.

9

Thromboembolism Incidence and Risk Factors in Multiple Myeloma After First Exposure to Immunomodulatory Drug-Based Regimens.

Patel JN, Robinson M, Jagosky M, Slaughter D, Arnall J, Jandrisevits E, Matusz-Fisher A, Atrash S, Paul B, Bhutani M, Voorhees P, Usmani SZ. Patel JN, et al. Among authors: arnall j. Clin Lymphoma Myeloma Leuk. 2021 Mar;21(3):188-198.e2. doi: 10.1016/j.clml.2020.11.015. Epub 2020 Nov 28. Clin Lymphoma Myeloma Leuk. 2021. PMID: 33339769 Review.

10

Incidence and management of adverse events associated with panobinostat in the treatment of relapsed/refractory multiple myeloma.

Moore DC, Arnall JR, Harvey RD. Moore DC, et al. Among authors: arnall jr. J Oncol Pharm Pract. 2019 Apr;25(3):613-622. doi: 10.1177/1078155218788706. Epub 2018 Jul 31. J Oncol Pharm Pract. 2019. PMID: 30060709 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results